Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 7, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Sale Price (Oct 30): GBP 13.99 per share
- Share Sale Price (Oct 31): GBP 14.03 per share
Material Changes
The filing details specific share movements executed by the SmithKline Beecham Employee Benefit Trust ("the Trust") on behalf of plan participants:
- October 30, 2006:
- 3,118 shares sold for the Bonus Investment Plan.
- 3,441 shares transferred to a Bonus Investment Plan participant.
- 1,860 shares sold for the Annual Investment Plan.
- 2,053 shares transferred to an Annual Investment Plan participant.
- October 31, 2006:
- 1,660 shares sold for the Annual Investment Plan.
- 5,544 shares transferred to an Annual Investment Plan participant.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J Heslop holds an interest in the fund shares similar to other beneficiaries.
Investor Verification Points
- Verify the total volume of shares sold versus transferred to understand net dilution or retention within the Trust.
- Confirm the current status of the SmithKline Beecham Employee Benefit Trust and its alignment with current GSK compensation structures.
- Check subsequent filings for any additional director transactions or changes in the Trust's holdings.